-
Streptavidin-Cy3 for Microrobot Assays
2026-09-11
Use Streptavidin-Cy3 to convert biotin-tagged antibodies, proteins, and nucleic acids into spatially resolved fluorescence readouts for biohybrid microrobot research. This practical guide connects labeling chemistry with matrix-penetration assays, tumor-spheroid imaging, flow cytometry, and troubleshooting controls.
-
Aclacinomycin A and Persistent rDNA Stress
2026-09-11
Aclacinomycin A, or Aclarubicin, is more than a cytotoxic anthracycline: its combined topoisomerase I/II activity provides a practical way to interrogate persistent DNA lesions, nucleolar stress, and apoptosis. This article connects the compound’s established pharmacology with evidence that unresolved ribosomal DNA damage can drive PML-nucleolar associations, while defining the validation steps needed before translating that model into biomarker or therapeutic hypotheses.
-
CIP2A, PKM2 Tetramers, and NSCLC Oxidative Metabolism
2026-09-10
The reference study identifies CIP2A as a metabolic regulator in non-small cell lung cancer, showing that it binds PKM2, promotes PKM2 tetramer formation through S287 phosphorylation, and redirects metabolism toward mitochondrial oxidative phosphorylation. Its mechanistic and in vivo findings support investigating CIP2A alongside glycolytic dependence as a context-specific strategy in NSCLC research, while also highlighting the limits of extending these results to untested drug combinations.
-
Polyclonal Goat Anti-Human IgG Antibody Guide
2026-09-10
This scenario-based guide explains how HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody, SKU K1205, can improve human IgG detection in immunofluorescence, Western blotting, flow cytometry, ELISA, and tissue workflows. It connects assay design, fluorescence controls, storage, interpretation, and vendor selection to practical laboratory decisions.
-
Ibrutinib (PCI-32765): From BTK to Assay Design
2026-09-09
Ibrutinib (PCI-32765) is a covalent BTK inhibitor for dissecting B-cell receptor signaling, chronic lymphocytic leukemia research, and autoimmune disease models. This article moves beyond basic workflow guidance to explain how target occupancy, genotype-stratified screening, and assay architecture should shape interpretation.
-
EPZ-6438: Practical EZH2 Inhibitor Workflows
2026-09-09
EPZ-6438 is a selective EZH2 inhibitor for connecting PRC2 biology with measurable chromatin, transcriptional, and cancer-cell phenotypes. This guide translates its biochemical profile into practical workflows for lymphoma, malignant rhabdoid tumor, and therapy-resistance studies.
-
Methotrexate Workflows for Permeability Research
2026-09-08
Build more informative Methotrexate studies by combining DHFR-centered cell assays with orthogonal proliferation, apoptosis, and inflammatory readouts. Biomimetic chromatography and MS add a practical membrane-interaction layer for permeability-focused optimization without treating chromatographic retention as a substitute for biological validation.
-
tRF16–ALKBH5 Signaling in Osteoarthritis
2026-09-08
This study identifies tRF16 as an overexpressed regulatory RNA that aggravates osteoarthritis by reducing ALKBH5 activity, destabilizing NFKBIA mRNA, and activating NF-κB signaling. Its combined patient-tissue, animal-model, and chondrocyte experiments provide a mechanistic framework for evaluating tRF16–ALKBH5 signaling as a potential biomarker and intervention axis.
-
Mitomycin C Workflows for Cancer Research
2026-09-07
Mitomycin C is an antitumor antibiotic that converts DNA damage into a controllable experimental stress for apoptosis, TRAIL-sensitization, and combination studies. This guide pairs practical handling and dosing workflows with the Notch1-YY1-ICAM1 immunotherapy findings, while clearly separating established evidence from exploratory HCC applications.
-
Capecitabine Workflows for Gastric Cancer Assembloids
2026-09-07
Capecitabine enables a practical comparison of tumor organoids and matched tumor–stroma assembloids, helping researchers test how microenvironmental context changes fluoropyrimidine response. This workflow combines tumor-selective activation biology, apoptosis readouts, and patient-derived model design for more informative preclinical oncology research.
-
Topotecan for Ovarian Cancer: Evidence and Implications
2026-09-05
This Cochrane review synthesized comparative evidence on topotecan-containing treatment for ovarian cancer, with particular attention to overall survival, progression outcomes, and toxicity. Its main contribution was to show why adding topotecan to a carboplatin–paclitaxel backbone should be judged by balanced benefit–harm endpoints rather than response activity alone.
-
Carboplatin Workflows for 2D and 3D Cancer Models
2026-09-04
Build more informative Carboplatin response assays by pairing controlled 2D dose–response experiments with 3D spheroid models. This workflow translates proteomic evidence into practical choices for ovarian and lung cancer research while addressing stock preparation, model variability, and combination-study pitfalls.
-
Oligo (dT) 25 Beads: mRNA Purification Guide
2026-09-04
Oligo (dT) 25 Beads selectively capture polyadenylated eukaryotic mRNA from total RNA or eukaryotic cells and tissues for downstream cDNA synthesis, RT-PCR, sequencing, and related applications. They should not be treated as a general total-RNA purification reagent or as a substitute for workflows targeting non-polyadenylated RNA.
-
Cholesterol and Intracellular LNP Trafficking
2026-09-03
A 2025 study developed a sensitive streptavidin–biotin-DNA and high-throughput imaging platform to resolve how lipid nanoparticle composition affects intracellular trafficking. The results identify cholesterol-driven accumulation in peripheral early endosomes as a delivery bottleneck, while showing that DSPC can reduce this adverse trafficking phenotype.
-
Hydroxytyrosol Workflows for Cardiovascular Research
2026-09-03
Build reproducible Hydroxytyrosol assays for oxidative stress modulation, inflammatory phenotyping, and cholesterol efflux. This practical guide translates recent olive-oil polyphenol findings into concentration-controlled workflows, assay controls, and troubleshooting decisions for cardiovascular health research.